BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, released an update from Chairman Richard Staelin, PhD, highlighting cost control measures, sales growth, and strategic progress. The company reported a small profit for calendar year 2025, driven by disciplined cost control, including office relocation and staff reductions, and initiatives to expand revenue in both over-the-counter (OTC) and professional markets.
The company has launched targeted advertising campaigns aimed at medical professionals and healthcare providers to increase awareness of its RecoveryRx device among surgeons, pain specialists, and rehabilitation providers seeking non-opioid pain management options. Additionally, consumer-focused social media advertising targeting Generation X consumers aims to boost brand visibility for drug-free chronic musculoskeletal pain relief.
BioElectronics is also pursuing outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx. The goal is to participate in a postoperative clinical study that could support future qualification for reimbursement under the federal NO PAIN Act initiative, which the company believes represents a meaningful long-term opportunity for broader adoption of non-opioid pain management technologies in surgical settings.
Internationally, the company continues arbitration proceedings in Singapore involving a former distributor, working with legal counsel and funders in China to protect its intellectual property and contractual rights. Despite the lengthy arbitration process, BioElectronics remains committed to protecting shareholder interests and expects to provide updates as developments occur.
A significant operational milestone is the advancement of the strategic distribution and licensing relationship with Electrome Corporation. Initial conditions of the supply agreement have been satisfied, and BioElectronics has received Electrome's initial purchase order. Manufacturing is underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products through its platform. This partnership provides another pathway to increase consumer awareness and access to the company's FDA-cleared, drug-free pain therapy products.
Chairman Staelin emphasized that while the Electrome relationship is important, it is part of a broader strategy encompassing clinical market development, direct professional outreach, consumer education, international opportunities, and protection of contractual and intellectual property rights. He noted growing interest in non-drug pain management solutions and expressed confidence in the company's position within the evolving electroceutical and non-opioid pain management markets. The company intends to continue advancing initiatives that support sustainable growth and build long-term value for shareholders.
Forward-looking statements in the release involve known and unknown risks, and actual results may differ materially from projections. The company undertakes no obligation to update forward-looking statements except as required by securities laws.
